4-hydroxymephenytoin has been researched along with omeprazole in 3 studies
| Studies (4-hydroxymephenytoin) | Trials (4-hydroxymephenytoin) | Recent Studies (post-2010) (4-hydroxymephenytoin) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
|---|---|---|---|---|---|
| 36 | 5 | 0 | 9,085 | 2,737 | 1,487 |
| Protein | Taxonomy | 4-hydroxymephenytoin (IC50) | omeprazole (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 3.1448 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wedlund, PJ; Wilkinson, GR | 1 |
| Hakusui, H; Ishizaki, T; Kaneko, S; Ohkubo, T; Otani, K; Ryokawa, Y; Sugawara, K; Suzuki, A; Tanaka, M; Yamamori, S | 1 |
| Bell, AR; Crewe, HK; Graham, MJ; Lennard, MS; Moorcraft, CL; Walker, L; Whittaker, EF | 1 |
3 other study(ies) available for 4-hydroxymephenytoin and omeprazole
| Article | Year |
|---|---|
In vivo and in vitro measurement of CYP2C19 activity.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Mephenytoin; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Stereoisomerism; Substrate Specificity | 1996 |
Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Half-Life; Humans; Japan; Male; Mephenytoin; Metabolic Clearance Rate; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1997 |
mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.
Topics: Algorithms; Animals; Cytochrome P-450 Enzyme System; Dextromethorphan; Dogs; Female; Humans; Isoenzymes; Kinetics; Liver; Male; Mephenytoin; Microsomes, Liver; Omeprazole; Protein Biosynthesis; RNA, Messenger; Warfarin | 2003 |